<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yaqin Peng</style></author><author><style face="normal" font="default" size="100%">Yutang Li</style></author><author><style face="normal" font="default" size="100%">Jinlin Hou</style></author><author><style face="normal" font="default" size="100%">Jian Sun</style></author><author><style face="normal" font="default" size="100%">Mingze Su</style></author><author><style face="normal" font="default" size="100%">Li, Yao</style></author><author><style face="normal" font="default" size="100%">Kuanhui Xiang</style></author><author><style face="normal" font="default" size="100%">Ling Yan</style></author><author><style face="normal" font="default" size="100%">Hui Zhuang</style></author><author><style face="normal" font="default" size="100%">Li, Tong</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The nucleotide changes within HBV core promoter/precore during the first 12weeks of nucleos(t)ide treatment might be associated with a better virological response</style></title><secondary-title><style face="normal" font="default" size="100%">Infect Genet Evol </style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2017</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://pubmed.ncbi.nlm.nih.gov/28088502/</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">49</style></volume><pages><style face="normal" font="default" size="100%">116-121</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">
&lt;strong class=&quot;sub-title&quot;&gt;Objectives:&amp;nbsp;&lt;/strong&gt;We aimed to study the dynamic changes of hepatitis B virus (HBV) core promoter/precore (CP/preC) sequences during antiviral treatment and their associations with virological responses.
&lt;strong class=&quot;sub-title&quot;&gt;Materials and methods:&amp;nbsp;&lt;/strong&gt;The baseline and 12-week CP/preC sequences (nts 1655-2014) were obtained from 52 chronic hepatitis B patients with positive hepatitis B e antigen (HBeAg), who received a 104-week lamivudine and adefovir dipivoxil combination therapy. The mutations within the CP/preC were analyzed against genotype specific reference sequences. The nucleotide change rates in individuals during therapy were analyzed in a pairwise comparison manner.
&lt;strong class=&quot;sub-title&quot;&gt;Results:&amp;nbsp;&lt;/strong&gt;There was no significant difference of the mutation rate at each nucleotide site between baseline and week 12 of treatment (P&amp;gt;0.05). The mutation rates of A1762T/G1764A and G1896A were found to decrease from 46.2% (24/52) at baseline to 36.5% (19/52) at week 12 (P=0.426) and from 28.8% (15/52) to 21.2% (11/52) (P=0.497), respectively. The nucleotide change rates varied from 0.0% - 7.8% in individuals [0.0% in Group 1 (N=26); 0.3% - 7.8% in Group 2 (N=26)] during the first 12-week treatment. HBV DNA levels in Group 2 were significantly lower than those in Group 1 throughout therapy (P&amp;lt;0.01) (e.g., 1.5±1.3log10&amp;nbsp;IU/ml vs. 2.6±1.0log10&amp;nbsp;IU/ml at week 104, P=0.001). At week 104 the rates of HBV DNA undetectable and HBeAg loss in Group 2 were significantly higher than those in Group 1 (P&amp;lt;0.05). Along with the increased nucleotide change rates, the rate of HBV DNA undetectable at week 104 tended to increase (odds ratio=0.323, 95% confidence interval=0.138-0.758, P&amp;lt;0.001).
&lt;strong class=&quot;sub-title&quot;&gt;Conclusion:&amp;nbsp;&lt;/strong&gt;Our findings suggested that the nucleotide changes within HBV CP/preC region during the first 12-week treatment might be associated with a better virological response.

&lt;strong class=&quot;sub-title&quot;&gt;Keywords:&amp;nbsp;&lt;/strong&gt;Antiviral response; Core promoter; Hepatitis B virus; Mutation; Nucleotide change; Precore.</style></abstract></record></records></xml>